Portage Biotech Inc (PRTG) has released an update.
Portage Biotech Inc. has announced a significant reduction in net loss from $104.7 million to $75.4 million in the fiscal year ending March 31, 2024, alongside the discontinuation of its iNKT clinical trial and a pause in patient enrollment for its ADPORT-601 clinical trial. Despite increased R&D expenses for its clinical trials, the company has successfully decreased G&A expenses and is actively seeking strategic alternatives, including potential partnerships, sales, mergers, or additional financing. Portage is dedicated to advancing cancer treatments and improving patient outcomes with its portfolio of multi-targeted therapies.
For further insights into PRTG stock, check out TipRanks’ Stock Analysis page.
